Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sunesis Pharmaceuticals |
---|---|
Information provided by: | Sunesis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00094159 |
The purpose of this study is to determine whether SNS-595 given intravenously weekly for 3 weeks is safe.
Condition | Intervention | Phase |
---|---|---|
Neoplasms |
Drug: SNS-595 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Arizona Cancer Center | |
Scottsdale, Arizona, United States | |
Arizona Cancer Center | |
Tucson, Arizona, United States | |
United States, California | |
Stanford University Medical Center | |
Stanford, California, United States | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States |
Study Director: | Daniel C. Adelman, MD | Sunesis Pharmaceuticals |
Study ID Numbers: | SPO-0002 |
Study First Received: | October 14, 2004 |
Last Updated: | May 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00094159 |
Health Authority: | United States: Food and Drug Administration |
Neoplasms |